Perioperative chemo plus serplulimab for specific stomach cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests whether adding serplulimab (an immune medicine) to standard chemotherapy before and/or around surgery can improve outcomes for people with certain locally advanced stomach cancer. You may get serplulimab or a placebo, and researchers will compare results to see if the immune add-on helps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18–80 and agree to participate by signing consent
- Your stomach (or stomach-area) cancer was confirmed by pathology and is pMMR but not dMMR
- Your cancer stage is T2 to T4b, with lymph-node involvement (or not) but no distant spread (M0)
- You must be well enough for treatment (ECOG performance status 0–1) and have at least 6 months to live
- Your blood, liver, kidney, and clotting test results must be within required ranges
- You must be able to provide tissue samples (biopsies and surgery) plus blood, stool, and urine samples
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This Phase 2 study looks at whether adding serplulimab to trastuzumab and chemotherapy after surgery can lower the chance of stomach cancer coming back. It is for people with HER2-positive stage II–III stomach adenocarcinoma who have already had curative surgery with lymph node removal.
This trial tests a new sequence of treatments for advanced stomach cancer that has spread to the lining of the abdomen. You would first get low-dose radiation, then a combination of immunotherapy, chemotherapy, and a special type of chemotherapy delivered directly into the belly, to see if it can control the cancer and improve quality of life.
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
Hear when a new Adenocarcinoma of Esophagogastric Junction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.